HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity

Biochemical and Biophysical Research Communications

Volumn 475, Issue 1, 2016, Pages 93-99

  Guo, Rui ^a   Cao, Li ^a   Guo, Wenjun ^a   Liu, Hui ^a   Xu, Hua ^a   Fang, Qi ^b   Hong, Zhangyong ^a  

^a NANKAI UNIVERSITY   (China)

^b Quzhou People's Hospital   (China)

Author keywords

HER2 target; Immunogenicity; Immunotoxins; Nonspecific toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOTOXIN; IMMUNOTOXIN HER2 PE25; IMMUNOTOXIN HER2 PE25 X7; IMMUNOTOXIN HER2 PE38; IMMUNOTOXIN HER2 PE38 X7; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; ERBB2 PROTEIN, HUMAN; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ACUTE TOXICITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; IMMUNOLOGY; NEOPLASMS; NUDE MOUSE; PSEUDOMONAS; TUMOR CELL LINE;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL LINE; CELL LINE, TUMOR; EXOTOXINS; FEMALE; HUMANS; IMMUNOTOXINS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PSEUDOMONAS; RECEPTOR, ERBB-2; VIRULENCE FACTORS;

EID: 84971207188     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.05.044     Document Type: Article

References (17)

1. M. Mathew, and R.S. Verma Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy Cancer Sci. 100 2009 1359 1365
2. M. Yamaizumi, E. Mekada, T. Uchida, and et al. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell Cell 15 1978 245 250
3. R.J. Kreitman, C.B. Siegall, V.K. Chaudhary, and et al. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in pseudomonas exotoxin Bioconjugate Chem. 3 1992 63 68
4. R.J. Kreitman, M.S. Tallman, T. Robak, and et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia J. Clin. Oncol. 30 2012 1822 1828
5. R.J. Kreitman, W.H. Wilson, J.D. White, and et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies J. Clin. Oncol. 18 2000 1622 1636
6. R. Hassan, S. Bullock, A. Premkumar, and et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers Clin. Cancer Res. 13 2007 5144 5149
7. J.E. Weldon, L. Xiang, O. Chertov, and et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity Blood 113 2009 3792 3800
8. W. Liu, M. Onda, B. Lee, and et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes Proc. Natl. Acad. Sci. USA 109 2012 11782 11787
9. R. Mazor, J.A. Eberle, X. Hu, and et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes Proc. Natl. Acad. Sci. USA 111 2014 8571 8576
10. L.H. Pai-Scherf, J. Villa, D. Pearson, T. Watson, and et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor Clin. Cancer Res. 5 1999 2311 2315
11. J. Löfblom, J. Feldwisch, V. Tolmachev, and et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 584 2010 2670 2680
12. J.E. Weldon, L. Xiang, J. Zhang, and et al. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity Mol. Cancer Ther. 12 2013 48 57
13. I. Mellman Endocytosis and molecular sorting Annu. Rev. Cell & Dev. Biol. 12 1996 575 625
14. R. Traini, and R.J. Kreitman Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin Bioconjugate Chem. 22 2011 736 740
15. B.M. Brenner, T.H. Hostetter, and H.D. Humes Glomerular permselectivity: barrier function based on discrimination of molecular size and charge Am. J. Physiol. 234 1978 455 460
16. J.K. Hansen, J.E. Weldon, L. Xiang, and et al. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice J. Immunother. 33 2010 297 304
17. M. Onda, M. Willingham, Q.C. Wang, and et al. Inhibition of TNF-α produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2 J. Immunol. 165 2000 7150 7156